StemRegenin-1 Attenuates Endothelial Progenitor Cell Senescence by Regulating the AhR Pathway-Mediated CYP1A1 and ROS Generation
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- CELLS12(15) · #2005 · 2023
- 피인용
- Web of Science 20Scopus 19
- FWCI (Scopus)
- 1.03
- JCR IF
- JCR 2022 6
- ISSN
- 2073-4409
저자
- 임혜지제1저자Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 장웅비Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 비노스 쿠마르 레티네스와란Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 최재우Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 이은지Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 박상미Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 정여름Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 하종성Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 윤지수Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 최영진Pusan Natl Univ, Sch Med, Dept Hematooncol, Yangsan 50612, South Korea
- Hong, Young Joon교신저자Chonnam Natl Univ, Chonnam Natl Univ Hosp, Sch Med, Dept Cardiol, Gwangju 61469, South Korea
- 권상모교신저자Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
초록
Endothelial progenitor cell (EPC)-based stem cell therapy is a promising therapeutic strategy for vascular diseases. However, continuous in vitro expansion for clinical studies induces the loss of EPC functionality due to aging. In this study, we investigated the effects of StemRegenin-1 (SR-1), an antagonist of aryl hydrocarbon receptor (AhR), on replicative senescence in EPCs. We found that SR-1 maintained the expression of EPC surface markers, including stem cell markers, such as CD34, c-Kit, and CXCR4. Moreover, SR-1 long-term-treated EPCs preserved their characteristics. Subsequently, we demonstrated that SR-1 showed that aging phenotypes were reduced through senescence-associated phenotypes, such as & beta;-galactosidase activity, SMP30, p21, p53, and senescence-associated secretory phenotype (SASP). SR-1 treatment also increased the proliferation, migration, and tube-forming capacity of senescent EPCs. SR-1 inhibited the AhR-mediated cytochrome P450 (CYP)1A1 expression, reactive-oxygen species (ROS) production, and DNA damage under oxidative stress conditions in EPCs. Furthermore, as a result of CYP1A1-induced ROS inhibition, it was found that accumulated intracellular ROS were decreased in senescent EPCs. Finally, an in vivo Matrigel plug assay demonstrated drastically enhanced blood vessel formation via SR-1-treated EPCs. In summary, our results suggest that SR-1 contributes to the protection of EPCs against cellular senescence.
키워드
StemRegenin-1human endothelial progenitor cellsAhR pathwayreactive oxygen speciesreplicative senescenceARYL-HYDROCARBON RECEPTORSTEM-CELLSMECHANISMSDISEASECD34ACTIVATIONEXPRESSIONEXPANSIONPROMOTEGENE
식별자
- Scopus EID
- 2-s2.0-85167595120
- WoS UID
- 001046163800001



로그인
연구물 목록으로